(2S)-2-[[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoyl]amino]-3-phenylpropanoic acid

We are (2S)-2-[[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoyl]amino]-3-phenylpropanoic acid CAS:84889-09-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (2S)-2-[[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
CAS.NO: 84889-09-8
Molecular Formula:C33H30N2O5
Molecular Weight:534.60200

Synonyms:
Fmoc-Phe-Phe-OH
Fmoc-L-Phe-L-Phe
Fmoc-L-Phe-L-Phe-OH
(S)-2-((S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-phenylpropanamido)-3-phenylpropanoic acid
L-Phenylalanine,N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl

Physical and Chemical Properties:
Density:  1.272±0.06 g/cm3
Boiling point:816.1±65.0 °C
Melting point: /
Flash point: /
Refractive index: /

Specification:
Appearance: White  Powder
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at -15ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Related News: It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.814-49-3 It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.Ethyl 3,4-dihydroxybenzoate “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”2,2,2-tricloro-1-etoxietanol CAS:515-83-3 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”In order to seize the highest point of profits, international industry giants have adjusted their development strategies, concentrated their energies on the two ends of the smile curve-research and development and end products, and shifted production links such as intermediates and APIs outward. A division of labor model has been formed.